April 23 (Reuters) - The U.S. Centers for Disease
Control and Prevention (CDC) on Tuesday alerted clinicians about
risks of counterfeit versions of AbbVie's ( ABBV ) Botox that
were given to consumers for cosmetic purposes in multiple
states.
The CDC, U.S. Food and Drug Administration (FDA) and state
and local partners are investigating reports of harmful
reactions among people who received injections of counterfeit
Botox.